Patheon opens new drug development suite

By Gareth Macdonald

- Last updated on GMT

Related tags Good manufacturing practice Pharmacology

Patheon hopes that a new pharmaceutical development services (PDS) suite at its facility in Whitby, Ontario will complete its “Quick to Clinic” offering and provide a rapid-response means of making solid dosage forms for trials.

The 2,500 square foot unit will house good manufacturing practice (GMP) compliant production lines capable of making drug supplies for Phase I and II clinical trials. The facility will also provide early-phase manufacturing capacity in the 1kg to 10kg range.

The PDS also houses multiple laboratory units capable of carrying out small scale dosage testing, powder-in-bottle manufacture, as well as tablet, capsule, oral dosage and nasal spray development.

A statement issued by PDS' vice president, Colin Minchom, detailed some of the unit’s potential advantages. He singled out the PDS’ “rapid response capabilities​” as being a feature that will: “significantly strengthen Patheon’s competitiveness in the pharmaceutical and biotechnology early development area​.”

Patheon’s president of North American operations, Terry Novak, added the firm “is committed to investing in its development services business and with this new capacity in Whitby; we can now offer rapid early phase development to our North American customers.”

Further evidence of Patheon’s efforts to develop its offering emerged earlier this month when the firm opened a new intermediate scale processing suite (ISPS) at its plant in Cincinnati, US.

In contrast with the PDS, the ISPS will focus on helping drugmakers to scale-up processes according to US Food and Drug Administration (FDA) quality by design (QbD) principles.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

Related suppliers

Follow us

Products

View more

Webinars